Oncology Phase 1 Deal Benchmarks — Ex-US

Understanding Oncology Deal Benchmarks at Phase 1

Phase 1 Oncology licensing deals in Ex-US territory command a median upfront payment of $40M, with values ranging from $19M at the low end to $68M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $218M to $576M, with a median of $397M. Royalty rates for oncology assets at this stage typically fall between 6.7% and 11.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.